OXi4503 + cytarabine

OXi4503 + cytarabine is an investigational combination therapy for relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). OXi4503 (combretastatin A1 diphosphate/CA1P) is a vascular disrupting agent that binds tubulin at the colchicine binding site to disrupt microtubule assembly and alter tumor bone marrow endothelial cell shape. This action downregulates intercellular adhesion molecules and releases quiescent tumor cells from the bone marrow niche, making them more susceptible to chemotherapy. Additionally, OXi4503 directly kills tumor cells via myeloperoxidase activation of a fluorquinone cytotoxic mediator. Cytarabine is an antimetabolite chemotherapeutic that inhibits DNA synthesis by acting as a pyrimidine analog. The combination has shown synergistic anti-leukemia activity in preclinical models and early-phase clinical trials with manageable toxicity profiles[2][5][8].

Other names

combretastatin A1 bis(phosphate)OXI 4503OXI4503OXI-4503